Needham & Company LLC Increases Teleflex (NYSE:TFX) Price Target to $170.00

Teleflex (NYSE:TFX - Get Free Report) had its price objective hoisted by investment analysts at Needham & Company LLC from $159.00 to $170.00 in a report issued on Tuesday, Marketbeat.com reports. The firm presently has a "buy" rating on the medical technology company's stock. Needham & Company LLC's price objective would indicate a potential upside of 22.91% from the stock's previous close.

Other equities analysts have also recently issued research reports about the company. Mizuho boosted their price objective on Teleflex from $140.00 to $145.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Zacks Research raised Teleflex from a "strong sell" rating to a "hold" rating in a report on Tuesday, April 28th. UBS Group lifted their price target on Teleflex from $145.00 to $158.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Wells Fargo & Company upped their price objective on Teleflex from $130.00 to $138.00 and gave the stock an "equal weight" rating in a research report on Friday, May 8th. Finally, Truist Financial raised their price objective on shares of Teleflex from $143.00 to $150.00 and gave the stock a "hold" rating in a research note on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $152.90.

Get Our Latest Analysis on TFX

Teleflex Stock Down 0.4%

NYSE:TFX opened at $138.31 on Tuesday. The firm has a market capitalization of $5.86 billion, a P/E ratio of -5.94, a PEG ratio of 0.93 and a beta of 0.81. Teleflex has a 1-year low of $100.18 and a 1-year high of $145.00. The company's fifty day moving average price is $132.87 and its 200-day moving average price is $125.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.60 and a quick ratio of 2.12.

Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The firm had revenue of $570.33 million during the quarter, compared to analysts' expectations of $559.59 million. During the same quarter last year, the company posted $3.73 earnings per share. The firm's revenue was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. As a group, equities research analysts anticipate that Teleflex will post 7.26 EPS for the current year.

Hedge Funds Weigh In On Teleflex

Large investors have recently bought and sold shares of the business. California State Teachers Retirement System boosted its position in Teleflex by 12,426.5% during the second quarter. California State Teachers Retirement System now owns 6,447,647 shares of the medical technology company's stock worth $817,304,000 after purchasing an additional 6,396,175 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of Teleflex in the second quarter valued at approximately $688,537,000. Jupiter Topco LLC acquired a new position in shares of Teleflex during the 2nd quarter worth approximately $550,456,000. Janus Henderson Group PLC raised its stake in shares of Teleflex by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company's stock worth $513,281,000 after buying an additional 45,199 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of Teleflex by 478.1% during the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company's stock valued at $287,603,000 after buying an additional 1,956,811 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company's stock.

About Teleflex

(Get Free Report)

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

Further Reading

• Five stocks we like better than Teleflex
• 3 Contrarian Trades for a Market That Looks Too Hot
• The Bull Case for D-Wave After a Disappointing Earnings Season
• Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
• Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Teleflex Right Now?

Before you consider Teleflex, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.

While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here